This study will test the safety and effectiveness of survodutide in treating cirrhosis caused by MASH. The goal is to see if the medication can prevent or delay liver complications and improve long-term outcomes.
Eligibility:
• Ages 18+
• Biopsy-confirmed compensated cirrhosis due to MASH (within past 5 years)